Nadia Luheshi

Nadia Luheshi

Company: AstraZeneca

Job title: Global Product Leader


MEDI1191, a Novel IL-12 mRNA Therapy for Intratumoral Injection 9:30 am

• Understand how IL-12 is a key driver of TH1 responses and anti-tumor immunity, but systemic recombinant IL-12 was poorly tolerated in early clinical trials • In preclinical models, intratumoral IL-12 mRNA drives IFNγ and CD8+ T cell-dependent anti-tumor immunity that is further enhanced by PD-L1 blockade • IT MEDI1191 is currently being evaluated in…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.